Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report

Precision Radiation Oncology

Yanyan Liang¹  Chunlei Xin¹  Shuguo Li¹  Meng Xiao¹  Yunliang Hao¹  Hongjing Zhou¹  Tongfeng Zhao¹  Shumei Li¹ 

[1] Jining NO.1 People's Hospital Jining China

关键词: chronic myeloid leukemia;    imatinib;    nilotinib;    tyrosine kinase inhibitors;   

DOI  :  10.1002/pro6.31

学科分类：医学（综合）

来源: Wiley

【 摘 要 】

Chronic myeloid leukemia (CML) is a clonal malignant hematopoietic disorder that arises in a hematopoietic stem cell. Its characteristic cytogenetic abnormality is an abnormal chromosome 22 called the Philadelphia (Ph) chromosome. The BCR‐ABL1 fusion gene in this chromosome can encode a tyrosine protein kinase and is the molecular basis of CML pathogenesis. The tyrosine kinase inhibitor (TKI) imatinib is the ‘gold standard’ therapy for the treatment of CML. However, around 30% of the patients develop imatinib resistance. In this report, we will illustrate a case of an adult female with acute transformation of CML whose imatinib resistance was reversed by nilotinib and has had a long‐term survival.

【 授权许可】

CC BY-NC-ND